These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 24899972)
1. Current molecular imaging positron emitting radiotracers in oncology. Zhu A; Shim H Nucl Med Mol Imaging; 2011 Mar; 45(1):1-14. PubMed ID: 24899972 [TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography imaging of cancer biology: current status and future prospects. Chen K; Chen X Semin Oncol; 2011 Feb; 38(1):70-86. PubMed ID: 21362517 [TBL] [Abstract][Full Text] [Related]
3. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong! Høilund-Carlsen PF Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. Development of PET probes for cancer imaging. Huang R; Wang M; Zhu Y; Conti PS; Chen K Curr Top Med Chem; 2015; 15(8):795-819. PubMed ID: 25732787 [TBL] [Abstract][Full Text] [Related]
6. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Vallabhajosula S Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348 [TBL] [Abstract][Full Text] [Related]
7. Target-specific delivery of peptide-based probes for PET imaging. Chen K; Conti PS Adv Drug Deliv Rev; 2010 Aug; 62(11):1005-22. PubMed ID: 20851156 [TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose. Zhu J; Pan F; Cai H; Pan L; Li Y; Li L; Li Y; Wu X; Fan H Front Med (Lausanne); 2022; 9():945602. PubMed ID: 36275809 [TBL] [Abstract][Full Text] [Related]
9. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients. Dimitrakopoulou-Strauss A; Strauss L Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388 [TBL] [Abstract][Full Text] [Related]
10. New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Gulyás B; Halldin C Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239 [TBL] [Abstract][Full Text] [Related]
11. PET imaging in urology: a rapidly growing successful collaboration. Farolfi A; Koschel S; Murphy DG; Fanti S Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721 [TBL] [Abstract][Full Text] [Related]
12. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging. Kumar R; Dhanpathi H; Basu S; Rubello D; Fanti S; Alavi A Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):50-65. PubMed ID: 18235421 [TBL] [Abstract][Full Text] [Related]
13. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Chua S; Gnanasegaran G; Cook GJ Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221 [TBL] [Abstract][Full Text] [Related]
14. The potential role of non-FDG-PET in the management of head and neck cancer. Heuveling DA; de Bree R; van Dongen GA Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481 [TBL] [Abstract][Full Text] [Related]
15. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology. Fukuda H; Kubota K; Matsuzawa T Tohoku J Exp Med; 2013 Jul; 230(3):155-69. PubMed ID: 23883588 [TBL] [Abstract][Full Text] [Related]
16. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970 [TBL] [Abstract][Full Text] [Related]
17. Role of Positron Emission Tomography in Imaging of Non-neurologic Disorders of the Head, Neck, and Teeth in Veterinary Medicine. Spriet M; Willcox JL; Culp WTN Front Vet Sci; 2019; 6():180. PubMed ID: 31245395 [TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography (PET) imaging with (18)F-based radiotracers. Alauddin MM Am J Nucl Med Mol Imaging; 2012; 2(1):55-76. PubMed ID: 23133802 [TBL] [Abstract][Full Text] [Related]
19. Can PET imaging facilitate optimization of cancer therapies? Kramer-Marek G; Capala J Curr Pharm Des; 2012; 18(18):2657-69. PubMed ID: 22512443 [TBL] [Abstract][Full Text] [Related]
20. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Shokeen M; Anderson CJ Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]